The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic che...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Online |
| Jezik: | engleski |
| Izdano: |
Frontiers Media SA
2021
|
| Teme: | |
| Online pristup: | 18152 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
| _version_ | 1869516100590370816 |
|---|---|
| author | Barbara Melosky Vera Hirsh |
| author_browse | Barbara Melosky Vera Hirsh |
| author_facet | Barbara Melosky Vera Hirsh |
| author_sort | Barbara Melosky |
| collection | Directory of Open Access Books |
| description | Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC. |
| format | Online |
| id | doab-20.500.12854ir-61307 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-613072024-03-30T23:21:51Z The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine Barbara Melosky Vera Hirsh R5-920 RC254-282 Epidermal growth factor receptors Non small cell lung cancer Echinoderm microtubule associated protein like 4 Quality of Life KRAS Anaplastic lymphoma kinase personalized medicine thema EDItEUR::M Medicine and Nursing Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC. 2021-02-12T06:33:18Z 2021-02-12T06:33:18Z 2016-01-19 14:05:46 2015 book 18152 16648714 9782889195435 https://directory.doabooks.org/handle/20.500.12854/61307 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/The_Treatment_of_Metastatic_Non-small_Cell_Lung_Cancer_(NSCLC)_in_New_Era_of_Personalised_Medicine/706#nogo http://journal.frontiersin.org/researchtopic/2504/the-treatment-of-metastatic-non-small-cell-lung-cancer-nsclc-in-new-era-of-personalised-medicine Frontiers Media SA 10.3389/978-2-88919-543-5 10.3389/978-2-88919-543-5 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889195435 140 open access |
| spellingShingle | R5-920 RC254-282 Epidermal growth factor receptors Non small cell lung cancer Echinoderm microtubule associated protein like 4 Quality of Life KRAS Anaplastic lymphoma kinase personalized medicine thema EDItEUR::M Medicine and Nursing Barbara Melosky Vera Hirsh The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
| title | The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
| title_full | The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
| title_fullStr | The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
| title_full_unstemmed | The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
| title_short | The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine |
| title_sort | treatment of metastatic non small cell lung cancer nsclc in new era of personalised medicine |
| topic | R5-920 RC254-282 Epidermal growth factor receptors Non small cell lung cancer Echinoderm microtubule associated protein like 4 Quality of Life KRAS Anaplastic lymphoma kinase personalized medicine thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC254-282 Epidermal growth factor receptors Non small cell lung cancer Echinoderm microtubule associated protein like 4 Quality of Life KRAS Anaplastic lymphoma kinase personalized medicine thema EDItEUR::M Medicine and Nursing |
| url | 18152 |
| work_keys_str_mv | AT barbaramelosky thetreatmentofmetastaticnonsmallcelllungcancernsclcinneweraofpersonalisedmedicine AT verahirsh thetreatmentofmetastaticnonsmallcelllungcancernsclcinneweraofpersonalisedmedicine AT barbaramelosky treatmentofmetastaticnonsmallcelllungcancernsclcinneweraofpersonalisedmedicine AT verahirsh treatmentofmetastaticnonsmallcelllungcancernsclcinneweraofpersonalisedmedicine |